• KOL
    • Rheumatoid Arthritis
    • Paul Emery
    • Paul Emery: Influence Statistics

      Paul Emery

      Paul Emery

      Show email address

      National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom | Rheumatology, Leeds Teaching ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Paul Emery:Expert Impact

      Concepts for whichPaul Emeryhas direct influence:Rheumatoid arthritis,Psoriatic arthritis,Patients rheumatoid arthritis,Ankylosing spondylitis,Arthritis rheumatoid,Early rheumatoid arthritis,Radiographic progression,Inflammatory arthritis.

      Paul Emery:KOL impact

      Concepts related to the work of other authors for whichfor which Paul Emery has influence:Rheumatoid arthritis,Ankylosing spondylitis,Autoimmune diseases,Systemic sclerosis,Necrosis factor,Monoclonal antibodies,Stem cells.

      KOL Resume for Paul Emery

      Year
      2022

      National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

      Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA, UK.

      Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds

      2021

      National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

      Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds

      2020

      Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Paul Emery is among the top experts in the world.
      Concept World rank
      rituximab clinical relapse #1
      abt494 placebo #1
      rheumatoid arthroscopy biopsy #1
      ldi tau #1
      antibodiesacpa #1
      ifx 36 months #1
      potential emt biomarker #1
      painful hand osteoarthritis #1
      infliximab treatment outcome #1
      repeat cycles #1
      ua early #1
      meacci #1
      cdc week #1
      tight control standard #1
      abbvie employee #1
      abatacept antibodies monoclonal #1
      icmmac #1
      cdc achievers patients #1
      tnf blocker therapy #1
      arthritis pain diclofenac #1
      ssz combination #1
      ocr500mtx #1
      subclinical enthesitis psa #1
      naïve early #1
      ust apr #1
      cle ldi #1
      secukinumab subcutaneous dose #1
      mtx pbo #1
      synovitis joint effusion #1
      efficacy sb210396 #1
      concomitant infliximab #1
      acpa positive individuals #1
      rheumatoid arthritis fcgr3a #1
      fatty romanus lesion #1
      phosphorylatedperk #1
      employee abbvie #1
      factorrf #1
      disease remission state #1
      subjects pbo #1
      mri bmo psoriasis #1
      fusion protein ctla4ig #1
      lte aba #1
      rituximab responses #1
      scores newra patients #1
      low structural progression #1
      ciclosporin aza #1
      osteitis bone erosion #1
      contact time difference #1
      26 joints #1
      ucb novartis #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Paul Emery

      KOL-Index: 28323

      BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.

      METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, ...

      Known for Tofacitinib Monotherapy | Rheumatoid Arthritis | Methotrexate Patients | Combination Therapy | Oral Strategy
      KOL-Index: 22837

      BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.

      METHODS: ...

      Known for Inadequate Response | Rheumatoid Arthritis | Upadacitinib 15 | Week Patients | 3 Study
      KOL-Index: 21805

      OBJECTIVE: To evaluate the effects of golimumab on inflammation/structural damage detected by magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA).

      METHODS: Methotrexate (MTX)-naive RA patients (n = 637) were randomized to placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX, or golimumab 100 mg plus MTX (subcutaneous golimumab every 4 weeks). Of these, 318 patients participated in an MRI substudy. MRIs (contrast-enhanced; 1.5T) of the wrist ...

      Known for Bone Erosion | Methotrexate Combination Therapy | Magnetic Resonance | Golimumab Mtx | Arthritis Patients
      KOL-Index: 21052

      BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.

      METHODS: This trial was done at 161 sites worldwide. ...

      Known for Methotrexate Patients | Low Disease | Rheumatoid Arthritis | Primary Endpoint | Activity Adalimumab
      KOL-Index: 19826

      OBJECTIVE: To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapies and to explore the pharmacokinetics and pharmacodynamics of rituximab in this population.

      METHODS: We evaluated primary efficacy and safety at 24 weeks in patients enrolled in the Randomized Evaluation of Long-Term Efficacy of Rituximab in RA (REFLEX) Trial, a ...

      Known for 24 Weeks | Primary Efficacy | Rituximab Monoclonal Antibodies | Rheumatoid Arthritis Refractory | Tumor Necrosis
      KOL-Index: 19010

      OBJECTIVES: This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment.

      METHODS: Patients with active disease on stable MTX (10-25 mg/week) were randomised to rituximab 2 x 500 mg (n=168), rituximab 2 x 1000 mg (n=172), or placebo (n=172). From week 24, patients not in remission (Disease Activity Score (28 joints) > or ...

      Known for Inadequate Response | Active Rheumatoid Arthritis | Rituximab Patients | Monoclonal Antibodies | Efficacy Safety
      KOL-Index: 18929

      BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.

      METHODS: In an ...

      Known for Methotrexate Patients | Rheumatoid Arthritis | 30 Weeks | Α Monoclonal Antibody | Necrosis Factor
      KOL-Index: 18907

      BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.

      METHODS: We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 ...

      Known for Adalimumab Monotherapy | Rheumatoid Arthritis | Patients Tocilizumab | Baseline Das28 | Phase 4
      KOL-Index: 17791

      BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.

      METHODS: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks ...

      Known for Ankylosing Spondylitis | Secukinumab Patients | 150 75 | Week Measure | Monoclonal Antibodies
      KOL-Index: 17615

      OBJECTIVE: To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.

      METHODS: Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was ...

      Known for Joint Damage | Mtx Infliximab | Early Rheumatoid Arthritis | Radiographic Progression Patients | Baseline Week
      KOL-Index: 17338

      OBJECTIVE: To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab.

      METHODS: Patients (n = 1049) with active RA for 3 years or less and no previous methotrexate treatment were randomly assigned (4 : 5 : 5) to receive methotrexate plus placebo or methotrexate plus infliximab 3 or 6 mg/kg at weeks 0, 2 and 6, and every 8 weeks thereafter to week 46. Disease activity ...

      Known for Methotrexate Monotherapy | Disease Activity States | Radiographic Progression Patients | Rheumatoid Arthritis | Necrosis Factor
      KOL-Index: 17302

      OBJECTIVE: To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone.

      METHODS: In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous ...

      Known for Certolizumab Pegol | Active Rheumatoid Arthritis | Placebo Mtx | Physical Function | Phase Iii
      KOL-Index: 17186

      OBJECTIVE: To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA).

      METHODS: MTX-naive patients with RA (n = 637) were randomized to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4). Subcutaneous injections of golimumab or placebo were administered every 4 weeks. The dosage of MTX/placebo capsules started at 10 mg/week ...

      Known for Golimumab Mtx | Acr50 Response | Rheumatoid Arthritis | Nonsteroidal Antibodies | Primary Point
      KOL-Index: 16699

      OBJECTIVE: To assess 2-year golimumab efficacy/safety in patients with active rheumatoid arthritis (RA) who had never taken methotrexate (MTX).

      METHODS: RA patients who had never taken MTX (n = 637) were randomized (1:1:1:1) to placebo + MTX (group 1), golimumab 100 mg + placebo (group 2), golimumab 50 mg + MTX (group 3), or golimumab 100 mg + MTX (group 4) every 4 weeks. Nonresponders based on week 28 swollen/tender joint counts changed treatment as follows: group 1 added golimumab 50 ...

      Known for Golimumab Mtx | Active Rheumatoid Arthritis | Phase Iii | Physical Function | Necrosis Factor
      KOL-Index: 16370

      OBJECTIVES: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).

      METHODS: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to ...

      Known for Active Psoriatic Arthritis | Patients Psa | Efficacy Safety | Pasi100 Response | Ixekizumab Adalimumab

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      #1
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      #2
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      #3
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      #4
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      #5
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      #6
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom | Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA, UK. | Leeds Institu

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.